- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03034668
Botanical Supplement Muscle Function and Lean Body Mass
The Acute and Chronic Influence of a Botanical Supplement on Muscle Function and Lean Body Mass
Purpose: To evaluate the acute and chronic effects of a botanical supplement on strength, muscle function, and lean body mass
Participants: The acute phase will include 30 participants, and the chronic phase will include 84 participants. All participants must be healthy recreationally active males between the ages of 18 and 35 years.
Procedures (methods):
Acute phase: Participants will complete three testing visits as part of as part of a cross-over design, during which strength and muscle function will be assessed prior to and following consumption of a supplement. The experimental supplement is a blend of the botanical extracts; treatment arms will include a full dose (FULL; 350 mg capsule), half dose (HALF; 175 mg plus maltodextrin), or placebo (PLA; maltodextrin).
Chronic phase: Body composition, muscle cross-sectional area, a complete blood count and metabolic panel, subjective surveys, and strength will be measured prior to and following an 8-week supervised resistance training program, in conjunction with daily supplementation of FULL, HALF, or PLA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina, Department of Exercise and Sport Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recreationally Active (1- 4 hours of exercise/ sports participation per week and no more than 1 hour of resistance training exercise per week) for the previous 12 weeks.
- BMI < 30 kg/m²
- Have not smoked in the past year.
- Participant has provided written and dated informed consent to participate in the study
- Participant is willing and able to comply with the protocol
- Participant is apparently healthy and free from disease, as determined by a health history questionnaire
- Participant agrees to abstain from caffeine, tobacco, alcohol, and exercise within 24 hours of testing visits
Exclusion Criteria:
- Participant has not used any dietary supplements within 12 weeks prior to enrollment and will not begin supplementation during the study. Potential supplements include but are not limited to Beta-alanine, Creatine, HMB, Carnosine, Taurine, androstenedione, DHEA, Whey protein, or a pre-workout supplement.
- Participant has gained or lost 10 lbs in the previous 2 months.
- Participant is currently enrolled in a separate clinical trial.
- Participant has participated in a clinical trial within the previous 2 months that includes modifications to their physical and/or diet.
- Participant has a known allergy or sensitivity to the placebo (maltodextrin) or active ingredients (Rhodiola & Rhaptonicum)
- Participant consumes more than 8 cups (1 cup = 6 oz) of coffee per day on a regular basis
- Participant consumes more than 3 alcoholic drinks per day.
- Participant uses recreational drugs daily.
- Previous physical symptoms causing a physician to recommend you to refrain from exercise.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Maltodextrin
|
Maltodextrin: 350 mg
|
Experimental: CS16-003 Full dose
350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
|
350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
|
Experimental: CS16-003 Half dose
175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
|
175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximal Isokinetic Leg Extension strength measured by dynamometry
Time Frame: Acute/Immediate
|
Acute/Immediate
|
Maximal Upper and Lower Body Strength measured by 1 repetition maximum
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bench Press Repetitions to Fatigue
Time Frame: 8 weeks
|
8 weeks
|
|
Leg Press Repetitions to Fatigue
Time Frame: 8 weeks
|
8 weeks
|
|
Body Composition-Lean Mass
Time Frame: 8 weeks
|
8 weeks
|
|
Body Composition-Fat Mass
Time Frame: 8 weeks
|
8 weeks
|
|
Muscle cross sectional area
Time Frame: 8 weeks
|
8 weeks
|
|
Change in Quality of Life Score from baseline to 8 weeks
Time Frame: baseline, 8 weeks
|
Quality of life from a visual analog scale (VAS) 0-100, with 0 = worst quality of life and 100=best quality of life.
|
baseline, 8 weeks
|
Change in Felt Arousal score from baseline to 8 weeks
Time Frame: baseline, 8 weeks
|
Felt arousal scale.
Scores range 1-6 with 1 being low arousal and 6 being high.
One score selected.
|
baseline, 8 weeks
|
Change in Mood score from baseline to 8 weeks
Time Frame: baseline; 8 weeks
|
Mood determined from a VAS.
0-100, with 0 = not depressed at all and 100 = most depressed.
|
baseline; 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Eric Ryan, PhD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 16-1991
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on CS16-003 Full dose
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina
-
Longbio PharmaRecruitingSeasonal Allergic RhinitisChina
-
University of TorontoCompleted
-
Colorado State UniversityNaturex-DbsCompletedAging | Endothelial DysfunctionUnited States
-
University of Sao Paulo General HospitalCompleted
-
University of OxfordEuropean CommissionCompletedMalaria | Plasmodium FalciparumUnited Kingdom
-
EpicentreKenya Medical Research Institute; LSHTM; Universite Abdou Moumouni de Niamey UAMActive, not recruitingPneumococcal CarriageNiger
-
University Hospital, AntwerpNot yet recruitingHypersensitivity | Anaphylaxis | Allergic Reaction | Perioperative Complication | Immediate Hypersensitivity | Hypersensitivity, Drug | Anaphylactic ReactionBelgium
-
Valneva Austria GmbHRecruitingChikungunya Virus InfectionDominican Republic, Honduras
-
The University of Texas Health Science Center,...Samsung ElectronicsCompletedChest X-ray for Clinical EvaluationUnited States